肿瘤异常蛋白及血清肿瘤标记物评估乳腺癌新辅助化疗效果的意义

目的：探讨肿瘤异常蛋白（tumor abnormal protein，TAP）及血清肿瘤标记物包括胚胎型抗原标记物CEA、黏蛋白抗原类标记物CA15-3和CA125在局部晚期乳腺癌新辅助化疗的疗效评价上是否有意义。方法：对接受新辅助化疗（部分患者接受靶向治疗）的68例局部晚期乳腺癌患者进行回顾性分析。按照化疗效果将其分为病理完全缓解（pCR）、部分缓解（PR）、病灶稳定（SD）和疾病进展（PD），其中pCR+PR定义为反应组，SD+PD为无反应组。所有患者在化疗前及手术前均进行了TAP、CEA、CA125及CA15-3的检测，比较其在反应组和无反应组的数值差异及数值变化是否具有统计学意义。结果：对化疗前后反应组和无反应组中各肿瘤标记物数值进行比较，除TAP在化疗后有统计学意义外（P<0.05），其余均无统计学意义（P>0.05）；对化疗前后两组中各标记物升降变化情况进行比较，TAP及CA15-3的变化有统计学意义（P<0.05），而CEA及CA125无统计学意义（P>0.05）。结论：TAP及CA15-3在评估乳腺癌新辅助化疗疗效方面可能存在一定意义。

Tumor abnormal protein (TAP) and serum tumor markers in assessing the effect of neoadjuvant chemotherapy of breast cancer

Objective: This article aimed to study the value of tumor abnormal protein (TAP) and serum tumor markers (including CEA, CA125 and CA 15-3) in the evolution of efficacy of neoadjuvant chemotherapy (NCT) in locally advanced breast cancer (LABC). Methods: In this retrospective study, 68 LABC patients received NCT were enrolled. They were classified into pathologic complete response (pCR), partial response (PR), stable disease (SD) and progression of disease (PD) according to the therapy efficacy (some patients received targeted therapy at the same time). We set group pCR and PR as reaction group, SD and PD as no reaction group. All patients received tests for TAP, CEA, CA125 and CA15-3 before and after NCT. We compared results of these tests and their changes to finds out whether there exists statistical difference between reaction group and no reaction group. Results: In accordance with the comparison among test figures before and after NCT, there were statistical significance in TAP after NCT between two groups (P<0.05). And comparison among the numerical changes showed that there were statistical significance in TAP and CA15-3 before and after NCT. Conclusion: TAP and CA15-3 may play a role in the evolution of NCT efficacy in LABC patients.